Answer to Question 1
D
Feedback:
Muromonab-CD3, the first monoclonal antibody approved for use, is a T-cellspecific antibody, that is available as an IV agent. It reacts as an antibody to human T cells, disabling the T cells, acting as an immune suppressor. Adalimumab is an antibody specific for human tumor necrosis factor. Cetuximab is an antibody specific to epidermal growth factor receptor sites. Rituximab is an antibody specific to sites on activated B lymphocytes.
Answer to Question 2
A
Feedback:
The main effect of nitrates seems to be related to the drop in blood pressure that occurs. The vasodilation causes blood to pool in veins and capillaries, decreasing preload, while the relaxation of the vessels decreases afterload. The combination of these effects greatly reduces the cardiac workload and the demand for oxygen, thus bringing the supply-and-demand ratio back into balance. Because coronary artery disease causes a stiffening and lack of responsiveness in the coronary arteries, the nitrates probably have very little effect on increasing blood flow through the coronary arteries, so it would be incorrect to say that the coronary arteries become much wider. Although both preload and afterload are reduced, this is an explanation that the patient would not understand, so it is inappropriate. Nitroglycerin does not promote growth of compensatory circulation.
Human Heart Model
human skin and pressure points
bone marrow human
Who Goes to College? Comparing Social Class and Ability in Determining College Attendance
Structure of the human immunodeficiency virus (HIV).
Varcarolis' Foundations of Psychiatric Mental Health Nursing: A Clinical Approach